We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App





Siemens Spotlights Innovations and Trends in Clinical Diagnostics and Point-of-Care Testing

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)

Siemens Healthineers (Erlangen, Germany) is highlighting its newest innovations and trends in clinical diagnostics and point-of-care testing at AACC 2023.

At the Siemens AACC 2023 booth, experts will provide a high-level overview of Atellica Integrated Automation. Powered for workflow and workforce efficiency, the company’s Atellica Solution delivers control and simplicity so labs can drive better outcomes. Experts will also demonstrate how the IMMULITE 2000 XPi immunoassay system can address common challenges faced by specialty laboratories. Providing multiple tests on a single, easy-to-use analyzer, the IMMULITE 2000 XPi immunoassay system makes it simple for labs to scale capabilities without disrupting regular day-to-day operations. It allows consolidation of routine and specialty testing, including allergy, on a single platform in labs with low to medium test volumes. Labs can incorporate specialty testing, including allergy, into routine workloads without interrupting the lab workflow in labs with medium to high test volumes.

Visitors to the Siemens booth at AACC 2023 also had the first view of the newly-launched Atellica CI Analyzer, a compact testing system designed to tackle lab challenges. The Atellica CI Analyzer1 for immunoassay and clinical chemistry testing is the newest addition to Siemens’ Atellica in vitro diagnostics portfolio. The Atellica CI Analyzer makes it possible for both standalone labs and satellite labs of wider health networks to have the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution—now condensed into a 1.9 square meters footprint ideal for smaller laboratories. The Atellica CI Analyzer aims to address labor shortage pain points and drive revenue growth, fostering agility beyond standardization and clinical equivalence.

Siemens is also demonstrating how labs can leverage the power of open connectivity with POC informatics. With its POCcelerator Data Management System, labs can simplify their POCT workflows and dramatically reduce workload for their staff. All patient results, quality controls, operators, reagents, and device data can be collected and reviewed in a clear and structured format in order to comply with regulatory guidelines. In addition, Siemens is demonstrating the utility of its non-invasive tests such as the ELF Test in the NALFD/NASH patient referral pathway, alongside its advancements in VWD diagnostics for improved management of bleeding patients. Among its solutions for critical care testing, Siemens is showcasing its epoc Blood Analysis System that securely delivers critical testing results at the patient-side in less than one minute and connects the entire team, so it doesn’t matter if the laboratory staff and caregivers work in different parts of the hospital.

Related Links:
Siemens Healthineers

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.